Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company (BMS) is dated August 17, 2006. The report addresses Item 8.01 (Other Events) concerning a statement from the Board of Directors regarding a Department of Justice (DOJ) criminal investigation into the settlement negotiations for the Plavix litigation.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on legal and governance matters rather than financial performance.
Material Changes and Legal Developments
- DOJ Investigation: The Board is treating the DOJ criminal investigation regarding the Plavix settlement with high seriousness and has directed full employee cooperation with the grand jury.
- Internal Findings: An ongoing internal investigation by outside counsel has not found evidence of unlawful conduct by BMS employees; these results are being shared with the DOJ.
- Legal Representation:
- Mary Jo White (Debevoise & Plimpton LLP) was retained to conduct an independent investigation of negotiations with Apotex.
- Kenneth Conboy (Latham & Watkins LLP) was retained by independent Board members to advise on corporate governance.
- Evan Chesler (Cravath, Swaine & Moore LLP) is representing the Company in a preliminary injunction motion against Apotex.
- Plavix Litigation: A preliminary injunction motion was filed to halt Apotex's sales of a generic Plavix version and to recall the product. A hearing is scheduled for the Friday following the filing date.
Management Commentary and Risks
The Board emphasizes that its paramount focus remains on the best interests of the Company and its shareholders. Management is providing frequent updates on the Plavix commercial plan and legal developments. The primary risk identified is the outcome of the DOJ investigation and the ongoing patent infringement litigation with Apotex regarding Plavix.
Key Facts for Investor Verification
- Verify the status of the DOJ criminal investigation into the Plavix settlement negotiations.
- Monitor the outcome of the preliminary injunction hearing against Apotex scheduled for the week of August 17, 2006.
- Review the findings of the independent investigation led by Mary Jo White regarding negotiations with Apotex.
- Assess the potential impact of the generic Plavix recall and sales halt on future revenue streams.